✦ LIBER ✦

Safety of high doses of Propionibacterium freudenreichii ET-3 culture in healthy adult subjects

✍ Scribed by Masayuki Uchida; Hiroshi Tsuboi; Masayo Takahashi (Arita); Atsushi Nemoto; Keisuke Seki; Hajime Tsunoo; Stephanie Martyres; Ashley Roberts

Book ID: 113965684
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 185 KB
Volume: 60
Category: Article
ISSN: 0273-2300
DOI: 10.1016/j.yrtph.2010.12.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety evaluation of Propionibacterium f

Safety evaluation of Propionibacterium freudenreichii ET-3 culture

✍ Masayuki Uchida; Nobuo Yoda; Masaki Terahara; Keisuke Seki; Sharon S.H. Choi; As 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 313 KB

Safety, Tolerability and Pharmacokinetic

Safety, Tolerability and Pharmacokinetics of Sugammadex Using Single High Doses (Up to 96 mg/kg) in Healthy Adult Subjects

✍ Dr Pierre A. M. Peeters, Michiel W. van den Heuvel, Emiel van Heumen, Paul C. C. 📂 Article 📅 2010 🏛 Springer International Publishing AG 🌐 English ⚖ 134 KB

Kinetics, safety and tolerability of (R)

Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects

✍ Kieran Clarke; Kirill Tchabanenko; Robert Pawlosky; Emma Carter; M. Todd King; K 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 289 KB

A phase I ascending single-dose study of

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

✍ Richat Abbas; Bruce A. Hug; Cathie Leister; Myriam El Gaaloul; Stephan Chalon; D 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 234 KB

Phase 3 trial evaluating the immunogenic

Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults

✍ Hopkins, Robert J.; Howard, Cris; Hunter-Stitt, Ericka; Kaptur, Paulina E.; Pleu 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 572 KB

Assessment of the immunogenicity and saf

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

✍ Hiroyuki Fukase; Hidetoshi Furuie; Yuji Yasuda; Ryoya Komatsu; Kenji Matsushita; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 397 KB